Novo Nordisk A/S (NVON)

1,935.000
-15.000(-0.77%)
  • Volume:
    981
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    1,935.000 - 1,952.000
  • Type:Equity
  • Market:Mexico
  • ISIN:US6701002056

NVON Comments

What is your sentiment on Novo Nordisk A/S?
or
Market is currently closed. Voting is open during market hours.

All Comments

(7)
  • Novo Nordisk announced plans to invest more than 17 billion Danish kroner ($2.58 billion) in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.
    0
    • sure, best company
      0
      • NVO WILL BUY ORMP AT 30 $
        0
        • and Gals..! :D
          0
          • Guys, think about this and USA market...and market all around the world. The same Type 2 diabetes drug semaglutide seems to work well against obesity.  This can be a massive hit! https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
            1
            • Seems that the importance of these results is being overlooked at the moment for some strange reason.  Might be a good idea to stay in long.
              0
            • Could be massive?? It will be now approved by FDA in US and soon EU all that remains is production cabability which was surprisingly not ready for such a demand (only US) so IMO this WILL exploded 10 fold what NN has expected., maybe more. Where do you find a obesity drug that helps? What obesity formulars has ever worked? This actually dos work.. Get ready!!!
              0
          • Very good long term investment
            0
            • Anyone got a view on how much the plans to reduce medical prices will affect the share price ?
              0
              • My bet is that the stock price will have an increase in growth on the long term. Not sure about short term as they might need to spend to expand production, however, they might get subsidies for this.
                0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.